Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency

Cancer Research

Volumn 74, Issue 13, 2014, Pages 3567-3578

  Muik, Alexander ^a   Stubbert, Lawton J ^b   Jahedi, Roza Z ^d   Geib, Yvonne ^a   Kimpel, Janine ^f   Dold, Catherine ^f   Tober, Reinhard ^f   Volk, Andreas ^a   Klein, Sabine ^b   Dietrich, Ursula ^a   Yadollahi, Beta ^c   Falls, Theresa ^b   Miletic, Hrvoje ^d,e   Stojdl, David ^c   Bell, John C ^b   Von Laer, Dorothee ^f  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d UNIVERSITY OF BERGEN   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BIOENGINEERING; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LEFT HEMISPHERE; MOUSE; NEUROTOXICITY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RIGHT HEMISPHERE; SINGLE DRUG DOSE; VESICULAR STOMATITIS VIRUS; VIRUS RECOMBINANT; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE, TUMOR; CRICETINAE; FEMALE; GENETIC VECTORS; GLIOBLASTOMA; GLYCOPROTEINS; HUMANS; IMMUNE EVASION; IMMUNITY, HUMORAL; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROTEIN ENGINEERING; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS;

EID: 84904052287     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3306     Document Type: Article

References (50)

1. Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol 2009;472:323-42.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
3. Zemp FJ, Corredor JC, Lun X, Muruve DA, Forsyth PA. Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev 2010;21: 103-17.
4. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotech 2012;30:658-70.
5. Ahmed M, Cramer SD, Lyles DS. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 2004;330:34-49.
6. Capo-chichi CD, Yeasky TM, Heiber JF, Wang Y, Barber GN, Xu XX. Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models. Gynecol Oncol 2010;116: 269-75.
7. Ebert O, Shinozaki K, Huang TG, Savontaus MJ, Garcia-Sastre A, Woo SL. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res 2003;63:3605-11.
8. Ozduman K, Wollmann G, Piepmeier JM, van den Pol AN. Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci 2008;28: 1882-93.
9. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000;6: 821-5.
10. Hadaschik BA, Zhang K, So AI, Fazli L, Jia W, Bell JC, et al. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res 2008;68:4506-10.
11. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4:263-75.
12. Lyles DS, Rupprecht CE. Fields virology. 5th ed. Lippincott Williams & Wilkins 2006. p. 1364-94.
13. Hastie E, Grdzelishvili VZ. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol 2012;93: 2529-45.
14. van den Pol AN, Dalton KP, Rose JK. Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol 2002;76:1309-27.
15. Johnson JE, Nasar F, Coleman JW, Price RE, Javadian A, Draper K, et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 2007;360: 36-49.
16. Quiroz E, Moreno N, Peralta PH, Tesh RB. A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am J Trop Med Hyg 1988;39:312-4.
17. Kelly EJ, Nace R, Barber GN, Russell SJ. Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol 2010;84:1550-62.
18. Edge RE, Falls TJ, Brown CW, Lichty BD, Atkins H, Bell JC. A let-7 microRNA-sensitive vesicular stomatitis virus demonstrates tumorspecific replication. Mol Ther 2008;16:1437-43.
19. Ayala-Breton C, Barber GN, Russell SJ, Peng KW. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther 2012;23:484-91.
20. Muik A, Kneiske I, Werbizki M, Wilflingseder D, Giroglou T, Ebert O, et al. Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J Virol 2011;85: 5679-84.
21. Clarke DK, Nasar F, Lee M, Johnson JE, Wright K, Calderon P, et al. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol 2007;81:2056-64.
22. Cooper D, Wright KJ, Calderon PC, Guo M, Nasar F, Johnson JE, et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol 2008;82:207-19.
23. Beyer WR, Westphal M, Ostertag W, von Laer D. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol 2002;76:1488-95.
24. Miletic H, Fischer YH, Giroglou T, Rueger MA, Winkeler A, Li H, et al. Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma. Clin Cancer Res 2007;13: 6761-8.
25. Miletic H, Fischer YH, Neumann H, Hans V, Stenzel W, Giroglou T, et al. Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins. Hum Gene Ther 2004;15:1091-100.
26. Beyer WR, Miletic H, Ostertag W, von Laer D. Recombinant expression of lymphocytic choriomeningitis virus strainWE glycoproteins: a single amino acid makes the difference. J Virol 2001;75:1061-4.
27. Seyfried TN, El-Abbadi M, Roy ML. Ganglioside distribution in murine neural tumors. Mol Chem Neuropathol 1991;17:147-67.
28. Boritz E, Gerlach J, Johnson JE, Rose JK. Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: entry by a pH-independent pathway. J Virol 1999;73:6937-45.
29. Muik A, Dold C, Geiss Y, Volk A, Werbizki M, Dietrich U, et al. Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy. J Mol Med (Berl) 2012.
30. Diallo JS, Vüahüa-Koskela M, Le Boeuf F, Bell J. Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains. Methods Mol Biol 2012;797:127-40.
31. Welsh RM,O'Donnell CL, Reed DJ, Rother RP. Evaluation of the Gala1- 3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses. J Virol 1998;72:4650-6.
32. Simon ID, van Rooijen N, Rose JK. Vesicular stomatitis virus genomic RNA persists in vivo in the absence of viral replication. J Virol 2010;84:3280-6.
33. Sur JH, Allende R, Doster AR. Vesicular stomatitis virus infection and neuropathogenesis in the murine model are associated with apoptosis. Vet Pathol 2003;40:512-20.
34. Pinschewer DD, Perez M, Jeetendra E, Bachi T, Horvath E, Hengartner H, et al. Kinetics of protective antibodies are determined by the viral surface antigen. J Clin Invest 2004;114:988-93.
35. Welsh RM. Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement. J Immunol 1977;118:348-54.
36. Wollmann G, Rogulin V, Simon I, Rose JK, van den Pol AN. Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J Virol 2010;84:1563-73.
37. Blackham AU, Northrup SA, Willingham M, D'Agostino RB Jr., Lyles DS, Stewart JHt. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery 2013;153: 333-43.
38. Paglino JC, van den Pol AN. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J Virol 2011;85:9346-58.
39. Zhang KX, Matsui Y, Hadaschik BA, Lee C, Jia W, Bell JC, et al. Downregulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death. Int J Cancer 2009; 127:830-8.
40. Finkelshtein M, Werman A, Novick D, Barak S, Rubinstein M. LDL receptor and its family members serve as the cellular receptor for vesicular stomatitis virus. PNAS 2013;110:7306-11.
41. Smelt SC, Borrow P, Kunz S, Cao W, Tishon A, Lewicki H, et al. Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor a-dystroglycan correlate with viral tropism and disease kinetics. J Virol 2001;75:448-57.
42. Zaccaria ML, Di Tommaso F, Brancaccio A, Paggi P, Petrucci TC. Dystroglycan distribution in adult mouse brain: a light and electron microscopy study. Neuroscience 2001;104:311-24.
43. Kunz S, Rojek JM, Kanagawa M, Spiropoulou CF, Barresi R, Campbell KP, et al. Posttranslational modification of a-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. J Virol 2005;79:14282-96.
44. Satz JS, Ostendorf AP, Hou S, Turner A, Kusano H, Lee JC, et al. Distinct functions of glial and neuronal dystroglycan in the developing and adult mouse brain. J Neurosci 2010;30:14560-72.
45. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004;64:4919-26.
46. Calogero A, Pavoni E, Gramaglia T, D'Amati G, Ragona G, Brancaccio A, et al. Altered expression of a-dystroglycan subunit in human gliomas. Cancer Biol Ther 2006;5:441-8.
47. Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med 2012;4:138ra77.
48. Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res 2012;72:1621-31.
49. Kueberuwa G, Cawood R, Seymour LW. Blood compatibility of enveloped viruses. Curr Opin Mol Ther 2010;12:412-20.
50. Planz O, Seiler P, Hengartner H, Zinkernagel RM. Specific cytotoxic T cells eliminate B cells producing virus neutralizing antibodies. Nature 1996;382:726-29.